A citation-based method for searching scientific literature

Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings. Diabetes Obes Metab 2021
Times Cited: 10







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Thomas A Zelniker, Marc P Bonaca, Remo H M Furtado, Ofri Mosenzon, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Circulation 2020
79
80

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
70

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
70

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu. Cardiovasc Diabetol 2019
54
60

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Wen-Jie Li, Xing-Qing Chen, Ling-Ling Xu, Yuan-Qing Li, Bi-Hui Luo. Cardiovasc Diabetol 2020
16
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan, Pao-Hsien Chu. Cardiovasc Diabetol 2020
8
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
40

Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.
Rachel R Huxley, Kristian B Filion, Suma Konety, Alvaro Alonso. Am J Cardiol 2011
275
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
40

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
40

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
Michael Böhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis T George, Anne Pernille Ofstad, Silvio E Inzucchi, David Fitchett, Stefan D Anker, Nikolaus Marx,[...]. Eur J Heart Fail 2020
29
40

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Salva R Yurista, Herman H W Silljé, Michiel Rienstra, Rudolf A de Boer, B Daan Westenbrink. Cardiovasc Diabetol 2020
10
30

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
30

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
353
30

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
63
30


Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
203
30



Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
199
20

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction.
Xiaodong Peng, Linling Li, Mengxia Zhang, Qianqian Zhao, Kui Wu, Rong Bai, Yanfei Ruan, Nian Liu. Front Physiol 2020
4
50

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.
E J Benjamin, P A Wolf, R B D'Agostino, H Silbershatz, W B Kannel, D Levy. Circulation 1998
20

Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies.
Christos A Goudis, Panagiotis Korantzopoulos, Ioannis V Ntalas, Eleftherios M Kallergis, Tong Liu, Dimitrios G Ketikoglou. Int J Cardiol 2015
67
20

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bruce Bode, Kaj Stenlöf, Daniel Sullivan, Albert Fung, Keith Usiskin. Hosp Pract (1995) 2013
167
20

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, James P Mancuso, Zhi Wei Jiang, Gregory Golm, Samuel S Engel, Brett Lauring. Diabetes Ther 2018
69
20

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
202
20

Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
Xiaowei Zhang, Zhiwei Zhang, Yajuan Yang, Ya Suo, Ruimeng Liu, Jiuchun Qiu, Yungang Zhao, Ning Jiang, Changle Liu, Gary Tse,[...]. Cardiovasc Diabetol 2018
20
20


Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
464
20

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
20

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle, Uli C Broedl. Clin Ther 2015
62
20

Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.
Chunxia Yao, Tina Veleva, Larry Scott, Shuyi Cao, Luge Li, Gong Chen, Prince Jeyabal, Xiaolu Pan, Katherina M Alsina, Issam Abu-Taha,[...]. Circulation 2018
164
20


Empagliflozin inhibits Na+ /H+ exchanger activity in human atrial cardiomyocytes.
Maximilian Trum, Johannes Riechel, Simon Lebek, Steffen Pabel, Samuel T Sossalla, Stephan Hirt, Michael Arzt, Lars S Maier, Stefan Wagner. ESC Heart Fail 2020
17
20

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
20

Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes.
Basil S Karam, Alejandro Chavez-Moreno, Wonjoon Koh, Joseph G Akar, Fadi G Akar. Cardiovasc Diabetol 2017
140
20

Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week.
Allen Wang, Jennifer B Green, Jonathan L Halperin, Jonathan P Piccini. J Am Coll Cardiol 2019
72
20


Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway.
Guang-Zhong Liu, Ting-Ting Hou, Yue Yuan, Peng-Zhou Hang, Jing-Jing Zhao, Li Sun, Guan-Qi Zhao, Jing Zhao, Jing-Mei Dong, Xiao-Bing Wang,[...]. Br J Pharmacol 2016
36
20

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
87
20

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
50
20


Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Laween Uthman, Marius Kuschma, Gregor Römer, Marleen Boomsma, Jens Kessler, Jeroen Hermanides, Markus W Hollmann, Benedikt Preckel, Coert J Zuurbier, Nina C Weber. Cardiovasc Drugs Ther 2021
10
20


Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zien Zhou, Meg J Jardine, Qiang Li, Brendon L Neuen, Christopher P Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Vlado Perkovic,[...]. Stroke 2021
8
25


Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Gilson C Fernandes, Amanda Fernandes, Rhanderson Cardoso, Jorge Penalver, Leonardo Knijnik, Raul D Mitrani, Robert J Myerburg, Jeffrey J Goldberger. Heart Rhythm 2021
6
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.